Next Article in Journal
Comparability of Portable and Desktop Spirometry: A Randomized, Parallel Assignment, Open-Label Clinical Trial
Previous Article in Journal
Efficacy Evaluation of Budesonide Nebulizer as an Adjunctive Medication in Post-Rain Asthma Acute Phase Attack
 
 
Advances in Respiratory Medicine is published by MDPI from Volume 90 Issue 4 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Via Medica.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Comorbidities Influence the Predictive Power of Hematological Markers for Mortality in Hospitalized COVID-19 Patients

by
Ashwaghosha Parthasarathi
1,
Chetak Kadabasal Basavaraja
2,
Sumalata Arunachala
2,
Shreya Chandran
2,
Hariharan Venkataraman
2,
Athira Satheesh
2 and
Padukudru Anand Mahesh
2,*
1
Allergy Asthma and Chest Institute, Krishnamurthypuram, Mysore, India
2
JSS Medical College, Bannimantap, Mysore, India
*
Author to whom correspondence should be addressed.
Adv. Respir. Med. 2022, 90(1), 49-59; https://doi.org/10.5603/ARM.a2022.0017
Submission received: 4 July 2021 / Revised: 14 September 2021 / Accepted: 14 September 2021 / Published: 28 January 2022

Abstract

Introduction: Coronavirus disease 2019 (COVID-19) pandemic has caused unprecedented mortality and has stretched the health infrastructure thin worldwide, especially in low- and middle-income countries. There is a need to evaluate easily available biomarkers for their clinical relevance for poor outcomes in severe cases of COVID-19. It is also known that comorbidities affect these biomarkers with or without COVID-19. We aimed to unearth the influence of comorbidities on feasible hematological predictive markers for mortality in hospitalized severe COVID-19 patients. Materials and Methods: This is a retrospective study done on severe COVID-19 hospitalized patients, diagnosed with RT polymerase chain reaction (n = 205), were investigated. Comorbidities associated with the patients were tracked and scored according to Charlson comorbidity index (CCI). CCI score of zero was grouped in A, those with CCI score 1–4 into group B and those with CCI scores ≥ 5 into group C. Correlation between hematological parameters and CCI scores was analyzed using Pearson correlation coefficient. Optimal cut-off and odds ratio was derived from receiver operating characteristic (ROC) curve analysis. Results: Among the 205 severe COVID-19 patients age, C-reactive protein (CRP), neutrophil lymphocyte ratio (NLR), derived NLR (dNLR), absolute neutrophil count (ANC) and total leukocyte count (TLC) were found to be statistically significant independent risk factors for predicting COVID-19 mortality (p < 0.01). In group A, cut off for CRP was 51.5 mg/L (odds ratio [OR]: 26.7; area under curve [AUC]: 0.867), TLC was 11,850 cells/mm³ (OR: 11.7; AUC: 0.731), NLR was 11.76 (OR: 14.3; AUC: 0.756), dNLR was 5.77 (OR: 4.89; AUC: 0.659), ANC was 13,110 cells/mm³ (OR: 1.68; AUC: 0.553). In group B, cut off for CRP was 36.5 mg/L (OR: 32.1; AUC: 0.886), TLC was 11,077 cells/mm³ (OR: 12.1; AUC: 0.722), NLR was 8.27 (OR: 18.9; AUC: 0.827), dNLR was 3.79 (OR: 9.26; AUC: 0.727), ANC was 11,420 cells/mm³ (OR: 2.42; AUC: 0.564). In group C, cut-off for CRP was 23.7 mg/L (OR: 32.7; AUC: 0.904), TLC was 10,480 cells/mm³ (OR: 21.2; AUC: 0.651), NLR was 6.29 (OR: 23.5; AUC: 0.647), dNLR was 1.93 (OR: 20.8; AUC: 0.698), ANC was 6650 cells/mm³ (OR: 2.45; AUC: 0.564). Conclusions: In severe COVID-19 patients, CRP was the most reliable biomarker to predict mortality followed by NLR. Presence, type, and number of co-morbidities influence the levels of the biomarkers and the clinically relevant cut-offs associated with mortality.
Keywords: COVID-19; SARS-CoV 2; comorbidities; prognostic indicators; hematological markers; neutrophil lymphocyte ratio; C-reactive protein COVID-19; SARS-CoV 2; comorbidities; prognostic indicators; hematological markers; neutrophil lymphocyte ratio; C-reactive protein

Share and Cite

MDPI and ACS Style

Parthasarathi, A.; Basavaraja, C.K.; Arunachala, S.; Chandran, S.; Venkataraman, H.; Satheesh, A.; Mahesh, P.A. Comorbidities Influence the Predictive Power of Hematological Markers for Mortality in Hospitalized COVID-19 Patients. Adv. Respir. Med. 2022, 90, 49-59. https://doi.org/10.5603/ARM.a2022.0017

AMA Style

Parthasarathi A, Basavaraja CK, Arunachala S, Chandran S, Venkataraman H, Satheesh A, Mahesh PA. Comorbidities Influence the Predictive Power of Hematological Markers for Mortality in Hospitalized COVID-19 Patients. Advances in Respiratory Medicine. 2022; 90(1):49-59. https://doi.org/10.5603/ARM.a2022.0017

Chicago/Turabian Style

Parthasarathi, Ashwaghosha, Chetak Kadabasal Basavaraja, Sumalata Arunachala, Shreya Chandran, Hariharan Venkataraman, Athira Satheesh, and Padukudru Anand Mahesh. 2022. "Comorbidities Influence the Predictive Power of Hematological Markers for Mortality in Hospitalized COVID-19 Patients" Advances in Respiratory Medicine 90, no. 1: 49-59. https://doi.org/10.5603/ARM.a2022.0017

Article Metrics

Back to TopTop